Pauline Funchain

stanford medicine

H指数:29

被引数:3,949

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chronic sequelae of immune-related adverse events

免疫相关不良事件的慢性后遗症

Expert Opinion on Drug Safety

IF3.1

2026-03-040

PRE

A phase II study of the AKT inhibitor TAS-117 in patients with advanced solid tumors and germline PTEN mutations

一项关于AKT抑制剂TAS-117在晚期实体瘤和胚系PTEN突变患者中的II期研究

ESMO Open

IF8.3

2025-12-300

OAAI

Correction: NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model

更正：NT-I7，一种新型长效白介素-7，在自体人源化黑色素瘤模型中促进抗PD-1疗效。

Scientific Reports

IF3.9

2025-12-180

OAAI

NT-I7, a novel long-acting interleukin-7, promotes anti-PD-1 efficacy in an autologous humanized melanoma model

NT-I7，一种新型长效白细胞介素-7，在自体人源化黑色素瘤模型中增强抗PD-1疗效。

Scientific Reports

IF3.9

2025-10-300

Germline Pathogenic Variants (gPVs) and Immune-Related Adverse Events (IRAEs) in Patients with Melanoma Receiving Immune Checkpoint Inhibitors (ICI)

生殖系致病性变异（gPVs）和免疫相关不良事件（IRAEs）在接受免疫检查点抑制剂（ICI）治疗的黑色素瘤患者中

Journal of the American Academy of Dermatology

IF11.8

2025-09-020

OAAI

Proceedings of the seventh annual Women in Melanoma Conference

第七届黑色素瘤女性大会会议录

Therapeutic Advances in Medical Oncology

IF4.2

2025-06-140

Genetic Landscape of Mucosal Melanoma: Identifying Pathogenic Germline Variants

PIGMENT CELL & MELANOMA RESEARCH

IF2.6

2025-03-010

PRE

Germline Pathogenic Variant–Positive Patients with Melanoma Exhibit Improved Response to Checkpoint Inhibitor Immunotherapy

携带黑色素瘤的生殖系致病变异阳性患者对检查点抑制剂免疫治疗的反应更佳

Journal of Investigative Dermatology

IF5.7

2025-01-130

PRE

Long-term cardiovascular outcomes of immune checkpoint inhibitor-related myocarditis: A large single-centre analysis

免疫检查点抑制剂相关心肌炎的长期心血管结局: 一项大型单中心分析

ESC HEART FAILURE

IF3.7

2024-10-310

How Many Doses of Infliximab Should Be Used in Immune Checkpoint Inhibitor-Induced Colitis? - A Retrospective Study

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2024-10-010

PRE

Germline cancer susceptibility in individuals with melanoma

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

IF11.8

2024-08-012

PRE

Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics

黑色素瘤患者间对免疫疗法的临床反应的自体人类临床前建模

JOURNAL FOR IMMUNOTHERAPY OF CANCER

IF10.6

2024-04-110

OAAI

Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in BRCA or BRCA-ness

CANCER RESEARCH

IF16.6

2024-04-050

PRE

Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial

CANCER RESEARCH

IF16.6

2024-03-221

PRE

Clinical and Immunologic Features of Germline Pathogenic Variant-Positive Patients with Melanoma

CLINICAL CANCER RESEARCH

IF10.2

2023-11-300

PRE

Long-Term Cardiovascular Outcomes of Immune Checkpoint Inhibitors-Related Myocarditis: A Large Single-Center Analysis

CIRCULATION

IF38.6

2023-11-070

PRE

MC1R signaling through the cAMP-CREB/ATF-1 and ERK-NF?B pathways accelerates G1/S transition promoting breast cancer progression

NPJ PRECISION ONCOLOGY

IF8

2023-09-077

OAAI

Reincarnating autoimmunity: Immune-related adverse events as new diseases

CLEVELAND CLINIC JOURNAL OF MEDICINE

IF4.1

2023-05-011

Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

CANCER RESEARCH

IF16.6

2023-04-040

PRE

Pauline Funchain

个人简介

教育背景

工作经历

荣誉奖项

研究方向